These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 16001413)

  • 1. Escaping Parkinson's disease: a neurologically healthy octogenarian with the LRRK2 G2019S mutation.
    Kay DM; Kramer P; Higgins D; Zabetian CP; Payami H
    Mov Disord; 2005 Aug; 20(8):1077-8. PubMed ID: 16001413
    [No Abstract]   [Full Text] [Related]  

  • 2. G2019S dardarin substitution is a common cause of Parkinson's disease in a Portuguese cohort.
    Bras JM; Guerreiro RJ; Ribeiro MH; Januario C; Morgadinho A; Oliveira CR; Cunha L; Hardy J; Singleton A
    Mov Disord; 2005 Dec; 20(12):1653-5. PubMed ID: 16149095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. G2019S LRRK2 mutation in familial and sporadic Parkinson's disease in Russia.
    Pchelina SN; Yakimovskii AF; Ivanova ON; Emelianov AK; Zakharchuk AH; Schwarzman AL
    Mov Disord; 2006 Dec; 21(12):2234-6. PubMed ID: 17044089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. G2019S LRRK2 mutation in French and North African families with Parkinson's disease.
    Lesage S; Ibanez P; Lohmann E; Pollak P; Tison F; Tazir M; Leutenegger AL; Guimaraes J; Bonnet AM; Agid Y; Dürr A; Brice A;
    Ann Neurol; 2005 Nov; 58(5):784-7. PubMed ID: 16240353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical features of Parkinson disease patients with homozygous leucine-rich repeat kinase 2 G2019S mutations.
    Ishihara L; Warren L; Gibson R; Amouri R; Lesage S; Dürr A; Tazir M; Wszolek ZK; Uitti RJ; Nichols WC; Griffith A; Hattori N; Leppert D; Watts R; Zabetian CP; Foroud TM; Farrer MJ; Brice A; Middleton L; Hentati F
    Arch Neurol; 2006 Sep; 63(9):1250-4. PubMed ID: 16966502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and positron emission tomography of Parkinson's disease caused by LRRK2.
    Hernandez DG; Paisán-Ruíz C; McInerney-Leo A; Jain S; Meyer-Lindenberg A; Evans EW; Berman KF; Johnson J; Auburger G; Schäffer AA; Lopez GJ; Nussbaum RL; Singleton AB
    Ann Neurol; 2005 Mar; 57(3):453-6. PubMed ID: 15732108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kin-cohort analysis of LRRK2-G2019S penetrance in Parkinson's disease.
    Goldwurm S; Tunesi S; Tesei S; Zini M; Sironi F; Primignani P; Magnani C; Pezzoli G
    Mov Disord; 2011 Sep; 26(11):2144-5. PubMed ID: 21714003
    [No Abstract]   [Full Text] [Related]  

  • 8. Frequency of the LRRK2 G2019S mutation in siblings with Parkinson's disease.
    Lesage S; Leclere L; Lohmann E; Borg M; Ruberg M; Dürr A; Brice A;
    Neurodegener Dis; 2007; 4(2-3):195-8. PubMed ID: 17596714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical heterogeneity of the LRRK2 G2019S mutation.
    Papapetropoulos S; Singer C; Ross OA; Toft M; Johnson JL; Farrer MJ; Mash DC
    Arch Neurol; 2006 Sep; 63(9):1242-6. PubMed ID: 16966501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations in LRRK2 other than G2019S are rare in a north American-based sample of familial Parkinson's disease.
    Pankratz N; Pauciulo MW; Elsaesser VE; Marek DK; Halter CA; Rudolph A; Shults CW; Foroud T; Nichols WC;
    Mov Disord; 2006 Dec; 21(12):2257-60. PubMed ID: 17078063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dyskinesias in patients with Parkinson's disease: effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation.
    Yahalom G; Kaplan N; Vituri A; Cohen OS; Inzelberg R; Kozlova E; Korczyn AD; Rosset S; Friedman E; Hassin-Baer S
    Parkinsonism Relat Disord; 2012 Nov; 18(9):1039-41. PubMed ID: 22703868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MAPK-pathway activity, Lrrk2 G2019S, and Parkinson's disease.
    White LR; Toft M; Kvam SN; Farrer MJ; Aasly JO
    J Neurosci Res; 2007 May; 85(6):1288-94. PubMed ID: 17385669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LRRK2 mutations in Spanish patients with Parkinson disease: frequency, clinical features, and incomplete penetrance.
    Gaig C; Ezquerra M; Marti MJ; Muñoz E; Valldeoriola F; Tolosa E
    Arch Neurol; 2006 Mar; 63(3):377-82. PubMed ID: 16533964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The G2019S LRRK2 mutation: another morbid burden for Ashkenazi Jews may provide new insights on sporadic Parkinson's disease.
    Melamed E
    Mov Disord; 2013 Dec; 28(14):1912-4. PubMed ID: 24307480
    [No Abstract]   [Full Text] [Related]  

  • 15. Analysis of the LRRK2 G2019S mutation in Alzheimer Disease.
    Zabetian CP; Lauricella CJ; Tsuang DW; Leverenz JB; Schellenberg GD; Payami H
    Arch Neurol; 2006 Jan; 63(1):156-7. PubMed ID: 16401756
    [No Abstract]   [Full Text] [Related]  

  • 16. The G2019S LRRK2 mutation is uncommon amongst Greek patients with sporadic Parkinson's disease.
    Kalinderi K; Fidani L; Bostantjopoulou S; Katsarou Z; Kotsis A
    Eur J Neurol; 2007 Oct; 14(10):1088-90. PubMed ID: 17880562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic screening for LRRK2 gene G2019S mutation in Parkinson's disease patients from Southern Italy.
    De Rosa A; Criscuolo C; Mancini P; De Martino M; Giordano IA; Pappatà S; Filla A; De Michele G
    Parkinsonism Relat Disord; 2009 Mar; 15(3):242-4. PubMed ID: 18621566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence and clinical features of common LRRK2 mutations in Australians with Parkinson's disease.
    Huang Y; Halliday GM; Vandebona H; Mellick GD; Mastaglia F; Stevens J; Kwok J; Garlepp M; Silburn PA; Horne MK; Kotschet K; Venn A; Rowe DB; Rubio JP; Sue CM
    Mov Disord; 2007 May; 22(7):982-9. PubMed ID: 17427941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel LRRK2 mutation in an Austrian cohort of patients with Parkinson's disease.
    Haubenberger D; Bonelli S; Hotzy C; Leitner P; Lichtner P; Samal D; Katzenschlager R; Djamshidian A; Brücke T; Steffelbauer M; Bancher C; Grossmann J; Ransmayr G; Strom TM; Meitinger T; Gasser T; Auff E; Zimprich A
    Mov Disord; 2007 Aug; 22(11):1640-3. PubMed ID: 17523199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parkinson's disease and LRRK2: frequency of a common mutation in U.S. movement disorder clinics.
    Kay DM; Zabetian CP; Factor SA; Nutt JG; Samii A; Griffith A; Bird TD; Kramer P; Higgins DS; Payami H
    Mov Disord; 2006 Apr; 21(4):519-23. PubMed ID: 16250030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.